雄黄(As4S4)为传统医学中按“以毒攻毒”法应用历史悠久的中药，临床上用于治疗血液系统及其它部位肿瘤，前期采用秀丽隐杆线虫研究发现雄黄能够通过下调Ras/MAPK信号通路从而显著干预ras突变（过度激活）引起的肿瘤。基于雄黄“以毒攻毒”治法及前期研究，科学的推测雄黄通过下调ras过度激活对K-ras突变诱导肺癌具有干预作用。为了阐明雄黄“以毒攻毒”治法对K-ras突变诱导肺癌的作用机制，本课题体外实验通过采用K-ras(G12V)突变诱导肺癌细胞和体内实验通过采用无胸腺裸鼠构建K-ras(G12V)突变诱导肺癌荷瘤小鼠证明雄黄对K-ras突变诱导肺癌的抗肿瘤活性。在此基础上，采用基因芯片、RT-PCR、免疫组化、westernblot等技术从分子水平上首次揭示雄黄“以毒攻毒”治法在K-ras突变诱导肺癌应用的分子调控机制，为雄黄在治疗肺癌的应用和抗肿瘤新药研发提供一定的理论依据。

Realgar (As4S4), a traditional Chinese medicine of “like cures like”, has been shown to be effective for treating hematologic malignancies and otherforms of cancers. In our previous studies, the results indicated that realgar can intervenetumor resulting from ras mutation by down-regulating Ras/MAPK signal pathway in C.elegans. In view of “like cures like” and early studies, we will infer that realgar could intervene lung cancer resulting from K-rasmutation by down-regulating overactivatedras.To clarify the action mechanism of realgarin“like cures like”for treating K-ras-mutant lung cancer, we will prove the effects on K-ras-mutant lung cancer of realgar by K-ras-mutant lung cancer cell lines and human xenograft tumorsin nude mice. On the basis of that, we will use the genechip, RT-PCR, immunochemistry, western blot to firstly reveal the molecular mechanism of realgar in“like cures like”for treating K-ras-mutant lung cancer. That will provide a theoretical basis for the application of realgar in the treatment of lung cancer and antitumor drug research.